Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Cortiment · 1 trial · 4 indications
Cmax (Maximum plasma concentration)
AUC0-t (area under the curve)
| Arm | Type | Description |
|---|---|---|
| Cortiment (Budesonide 9 mg prolonged release tablet) | ACTIVE_COMPARATOR | - |
| Budesonide 9 mg prolonged release tablet | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Cortiment | DRUG | Budesonide 9 mg prolonged release tablets |
| Budesonide | DRUG | Experimental (Budesonide 9 mg prolonged release tablets) |
Inclusion Criteria: 1. Normal healthy human adult male and non- pregnant female volunteers between 18-45 years (both ages inclusive) of age. 2. Who is given written informed consent and are willing to participate in the study. 3. Body Mass Index of 18.50 to 30.00 Kg/m2 (both inclusive). 4. No evide...
Cortiment is a small molecule drug being developed by Abbott Laboratories for use in healthy subjects. It is currently in Phase 1 clinical development, with studies focused on bioequivalence in healthy human adult volunteers. The drug is not approved and remains investigational.
Cortiment is being developed by Abbott Laboratories, a company traded under the ticker ABT. The drug is currently in Phase 1 clinical development for use in healthy subjects.
Cortiment is in Phase 1 clinical development. It has completed one Phase 1 trial, which was a bioequivalence study in healthy human adult subjects. The drug is investigational and not yet approved.
Cortiment has one completed Phase 1 clinical trial, NCT05519514, titled 'Bio-Equivalence Study of Budesonide Prolonged-release Tablets 9 Mg In Healthy Human Adult Subjects.' The trial enrolled 56 participants in India and was active-controlled, though not double-blinded.
Cortiment is being studied as a budesonide prolonged-release tablet. The Phase 1 trial NCT05519514 evaluated the bioequivalence of Cortiment 9 mg tablets in healthy subjects, indicating the drug's active ingredient is budesonide.